202 related articles for article (PubMed ID: 32651043)
1. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
[TBL] [Abstract][Full Text] [Related]
2. Computed Tomography-Defined Sarcopenia in Outcomes of Patients with Unresectable Hepatocellular Carcinoma Undergoing Radioembolization: Assessment with Total Abdominal, Psoas, and Paraspinal Muscles.
Wu CH; Ho MC; Chen CH; Liang JD; Huang KW; Cheng MF; Chang CK; Chang CH; Liang PC
Liver Cancer; 2023 Dec; 12(6):550-564. PubMed ID: 38058418
[TBL] [Abstract][Full Text] [Related]
3. Computed tomography-based sarcopenia in patients receiving peritoneal dialysis: Correlation with lean soft tissue and survival.
Wu CH; Chao CT; Liang PC; Shih TTF; Huang JW
J Formos Med Assoc; 2022 Feb; 121(2):500-509. PubMed ID: 34274192
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
[TBL] [Abstract][Full Text] [Related]
5. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
[TBL] [Abstract][Full Text] [Related]
6. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
7. Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model.
Thormann M; Heitmann F; Wrobel V; Heinze C; March C; Hass P; Damm R; Surov A; Pech M; Omari J
Dig Dis; 2023; 41(6):957-966. PubMed ID: 37385234
[TBL] [Abstract][Full Text] [Related]
8. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.
Fang Z; Du F; Shang L; Liu J; Ren F; Liu Y; Wu H; Liu Y; Li P; Li L
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):317-324. PubMed ID: 33063547
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume.
Imai K; Takai K; Watanabe S; Hanai T; Suetsugu A; Shiraki M; Shimizu M
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28937616
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.
Sawada K; Saitho Y; Hayashi H; Hasebe T; Nakajima S; Ikuta K; Fujiya M; Okumura T
JGH Open; 2019 Aug; 3(4):329-337. PubMed ID: 31406927
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
Meyer HJ; Strobel A; Wienke A; Surov A
Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis.
Nishikawa H; Enomoto H; Ishii A; Iwata Y; Miyamoto Y; Ishii N; Yuri Y; Takata R; Hasegawa K; Nakano C; Nishimura T; Yoh K; Aizawa N; Sakai Y; Ikeda N; Takashima T; Iijima H; Nishiguchi S
Hepatol Res; 2017 Sep; 47(10):1042-1052. PubMed ID: 27862791
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis.
Kuo MH; Tseng CW; Hsu CS; Chen YC; Kao IT; Wu CY; Shao SC
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173893
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis.
Begini P; Gigante E; Antonelli G; Carbonetti F; Iannicelli E; Anania G; Imperatrice B; Pellicelli AM; Fave GD; Marignani M
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):107-114. PubMed ID: 28051799
[TBL] [Abstract][Full Text] [Related]
15. Is rectus abdominis thickness associated with survival among patients with liver cirrhosis? A prospective cohort study.
Ciocîrlan M; Mănuc M; Diculescu M; Ciocîrlan M
Sao Paulo Med J; 2019; 137(5):401-406. PubMed ID: 31721939
[TBL] [Abstract][Full Text] [Related]
16. Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection.
Yabusaki N; Fujii T; Yamada S; Suzuki K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2016 Jun; 30():136-42. PubMed ID: 27154615
[TBL] [Abstract][Full Text] [Related]
17. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
[TBL] [Abstract][Full Text] [Related]
18. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
Cheng TY; Lee PC; Chen YT; Chao Y; Hou MC; Huang YH
Sci Rep; 2020 Oct; 10(1):18375. PubMed ID: 33110117
[TBL] [Abstract][Full Text] [Related]
19. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
Kang MK; Park JG; Lee HJ; Kim MC
J Gastroenterol Hepatol; 2019 Sep; 34(9):1633-1640. PubMed ID: 30667551
[TBL] [Abstract][Full Text] [Related]
20. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M; Jin Q; Wang H; Li Y
Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
